Bio-Rad Laboratories, Inc.
BIO
$238.68
-$2.34-0.97%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -4.16% | -2.00% | 2.79% | -6.26% | -9.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.16% | -2.00% | 2.79% | -6.26% | -9.76% |
| Cost of Revenue | -3.38% | 3.42% | -0.88% | -11.26% | -9.55% |
| Gross Profit | -4.84% | -6.66% | 6.02% | -1.87% | -9.94% |
| SG&A Expenses | -8.08% | -1.53% | -0.33% | -5.69% | -6.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.47% | 3.98% | 8.17% | -9.00% | -9.08% |
| Operating Income | 10.06% | -38.97% | -29.16% | 11.77% | -16.50% |
| Income Before Tax | -83.02% | -312.17% | 528.45% | -85.70% | 478.93% |
| Income Tax Expenses | -81.90% | -345.49% | 575.79% | -83.57% | 575.62% |
| Earnings from Continuing Operations | -83.33% | -304.67% | 514.71% | -86.32% | 456.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.33% | -304.67% | 514.71% | -86.32% | 456.68% |
| EBIT | 10.06% | -38.97% | -29.16% | 11.77% | -16.50% |
| EBITDA | 6.98% | -26.48% | -19.45% | 8.89% | -8.94% |
| EPS Basic | -82.99% | -310.48% | 540.07% | -92.62% | 477.73% |
| Normalized Basic EPS | 12.92% | -36.80% | -31.05% | 16.28% | -23.26% |
| EPS Diluted | -82.97% | -310.69% | 541.21% | -92.62% | 479.74% |
| Normalized Diluted EPS | 12.93% | -36.75% | -30.85% | 16.28% | -22.92% |
| Average Basic Shares Outstanding | -2.02% | -2.76% | -3.96% | -3.27% | -3.64% |
| Average Diluted Shares Outstanding | -2.04% | -2.84% | -4.24% | -3.27% | -4.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |